Cilcare is a biotechnology company dedicated to leveraging auditory sciences to shape the future of care through early diagnosis and targeted treatment. Employing advance auditory measurements, the company develops a pioneering pipeline of therapies for future hearing solutions, with a specific emphasis on cochlear synaptopathy — an ailment associated with difficulty hearing in noisy environments, affecting 1 in 4 individuals aged 45 and above. Cilcare’s commitment extends to harnessing the power of auditory measurements to revolutionize early diagnosis and targeted treatment for hearing-related issues, neurocognitive and inflammatory diseases. The company actively collaborates with life sciences partners to support the development of therapies for various auditory conditions, primarily focusing on sensorineural hearing loss, synaptopathy, ototoxicity, and tinnitus.